Lifeboat Foundation

These longstanding challenges are both related to how functionals behave when presented with a system that exhibits “fractional electron character.” By using a neural network to represent the functional and tailoring our training dataset to capture the fractional electron behaviour expected for the exact functional, we found that we could solve the problems of delocalization and spin symmetry-breaking. Our functional also showed itself to be highly accurate on broad, large-scale benchmarks, suggesting that this data-driven approach can capture aspects of the exact functional that have thus far been elusive.

For years, computer simulations have played a central role in modern engineering, making it possible to provide reliable answers to questions like “will this bridge stay up?” to “will this rocket make it into space?” As technology increasingly turns to the quantum scale to explore questions about materials, medicines, and catalysts, including those we’ve never seen or even imagined, deep learning shows promise to accurately simulate matter at this quantum mechanical level.

Researchers in China have developed a new three-pronged method to fight liver cancer that shows promise in tests in mice. The technique combines drugs and CRISPR-Cas9 gene editing into lipid nanoparticles, then activates them with ultrasound.

One emerging treatment against cancer is known as sonodynamic therapy (SDT), which involves delivering drugs to the tumor and then activating them with ultrasound pulses. That produces reactive oxygen species (ROS) that can induce oxidative stress on the cancer cells to kill them. Unfortunately, cancer can counter this attack with antioxidant enzymes, reducing the method’s efficiency.

So for the new study, the researchers investigated a way to remove that defense system. The team suspected that they could use CRISPR to switch off a gene called NFE2L2, which cancer cells use to set off their antioxidant defenses. The team packaged both the CRISPR machinery and the ROS-producing drugs into lipid nanoparticles, which could be activated with ultrasound pulses.

Many intractable diseases are the result of a genetic mutation. Genome editing technology promises to correct the mutation and thus new treatments for patients. However, getting the technology to the cells that need the correction remains a major challenge. A new study led by CiRA Junior Associate Professor Akitsu Hotta and in collaboration with Takeda Pharmaceutical Company Limited as part of the T-CiRA Joint Research Program reports how lipid nanoparticles provide an effective means for the delivery to treat Duchenne muscular dystrophy (DMD) in mice.

Last year’s Nobel Prize for Chemistry to the discoverers of CRISPR-Cas9 cemented the impact of genome editing technology. While CRISPR-Cas9 can be applied to agriculture and livestock for more nutritious food and robust crops, most media attention is on its medical potential. DMD is just one of the many diseases that researchers foresee a treatment using CRISPR-Cas9.

“Oligonucleotide drugs are now available for DMD, but their effects are transient, so the patient has to undergo weekly treatments. On the other hand, CRISPR-Cas9 effects are long lasting,” said Hotta.

Gene therapy is a powerful developing technology that has the potential to address myriad diseases. For example, Huntington’s disease, a neurodegenerative disorder, is caused by a mutation in a single gene, and if researchers could go into specific cells and correct that defect, theoretically those cells could regain normal function.

A major challenge, however, has been creating the right “delivery vehicles” that can carry genes and molecules into the cells that need treatment, while avoiding the cells that do not.

Now, a team led by Caltech researchers has developed a gene-delivery system that can specifically target brain cells while avoiding the liver. This is important because a gene therapy intended to treat a disorder in the brain, for example, could also have the side effect of creating a toxic immune response in the liver, hence the desire to find delivery vehicles that only go to their intended target. The findings were shown in both mouse and marmoset models, an important step towards translating the technology into humans.

Since then, Sophia has spoken to audiences across the globe (in multiple languages), been interviewed on countless TV shows, and even earned a United Nations title (a first for a non-human).

Today, she’s arguably the most famous robot in the world, but she’s isn’t going to be unique for much longer. Her maker, Hanson Robotics, has announced plans to begin mass-producing Sophia the robot this year — so that she can help the world cope with the pandemic.

Exploring The Longevity Secrets Of “Methuselah’s Zoo” For Healthy Human Aging — Dr. Steven Austad, University of Alabama at Birmingham.

Dr. Steven Austad (https://www.stevenaustad.com/) is Distinguished Professor and Protective Life Endowed Chair in Healthy Aging Research, Department of Biology, University of Alabama at Birmingham (UAB), and Scientific Director of the American Federation for Aging Research (https://www.uab.edu/cas/biology/people/faculty/steven-n-austad).

Continue reading “Dr Steven Austad — UAB — Exploring The Longevity Secrets Of Methuselah’s Zoo For Healthy Human Aging” »

It’s long been known that exposure to radiation damages DNA, but a new study has found an additional risk for astronauts: DNA replication is more prone to errors in microgravity.

Scientists tested whether enzymes accurately copy DNA in cells during microgravity — the weightlessness produced during the freefall of a jet on a parabolic flight pattern. When the so-called “vomit comet” descends more than 2 miles in 20 seconds, the near-weightlessness replicates conditions in space. Accurate DNA replication in space is crucial for astronauts and the future of space travel.

“So-called DNA polymerases are essential enzymes that copy and repair DNA. Inevitably, they aren’t perfect: even under optimal conditions, they sometimes make mistakes. Here, we show that DNA polymerases derived from the bacterium E. coli are considerably more prone to errors under microgravity, such as occurs in space,” said Aaron Rosenstein of the University of Toronto, corresponding author of the study published in Frontiers in Cell and Developmental Biology.

The pan-coronavirus one that’s variant-proof.

Science.org/doi/full/10.11… See more.

COVID-19 vaccines go through many tests for safety and effectiveness and are then monitored closely.

A new technology is allowing one company to produce full-spectrum cannabis without growing the plant itself.

Sounds like something out of a science fiction movie, but it’s very real. In what could be a global first, this week, a publicly traded Canadian-Israeli biotech firm company, BioHarvest Sciences, will announce that it has managed to produce at least 10kg of full-spectrum cannabis without the plant itself.

According to information procured exclusively, the biomass in question was created using the company’s proprietary BioFarming technology platform, which allows it to grow natural plant cells in bioreactors. In addition, management assures, the product is not genetically modified, and is “uniquely consistent and clean.” This could provide an interesting solution to two of the cannabis industry’s main pain points: product variability and contamination — the aseptic, controlled environment means the product isn’t affected by fungi, yeast, mold or any other contaminants or pesticides.

Continue reading “Producing Cannabis Biomass Without Growing A Cannabis Plant: How One Company Is Doing It” »